45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
1,869
Insurances with rates
33
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 096 | BACTERIAL AND TUBERCULOUS INFECTIONS OF NERVOUS SYSTEM WITHOUT CC/MCC | $73,978 | $48,086 | — | — | 58 |
| 643 | ENDOCRINE DISORDERS WITH MCC | $72,855 | $47,356 | — | — | 57 |
| 981 | EXTENSIVE O.R. PROCEDURES UNRELATED TO PRINCIPAL DIAGNOSIS WITH MCC | $68,340 | $44,421 | — | — | 57 |
| 377 | GASTROINTESTINAL HEMORRHAGE WITH MCC | $63,332 | $41,166 | — | — | 54 |
| 864 | FEVER AND INFLAMMATORY CONDITIONS | $52,098 | $33,864 | — | — | 57 |
| 559 | AFTERCARE, MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITH MCC | $48,822 | $31,734 | — | — | 54 |
| 949 | AFTERCARE WITH CC/MCC | $48,553 | $31,559 | — | — | 57 |
| 982 | EXTENSIVE O.R. PROCEDURES UNRELATED TO PRINCIPAL DIAGNOSIS WITH CC | $46,403 | $30,162 | — | — | 57 |
| 560 | AFTERCARE, MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITH CC | $43,548 | $28,306 | — | — | 57 |
| 281 | ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH CC | $43,123 | $28,030 | — | — | 57 |
| RX-79826 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $39,602 | $25,741 | — | — | 108 |
| 291 | HEART FAILURE AND SHOCK WITH MCC | $38,818 | $25,232 | — | — | 58 |
| 056 | DEGENERATIVE NERVOUS SYSTEM DISORDERS WITH MCC | $30,660 | $19,929 | — | — | 57 |
| RX-224155 | BENRALIZUMAB 30 MG/ML SUBCUTANEOUS SYRINGE | $29,290 | $19,039 | — | — | 108 |
| 433 | CIRRHOSIS AND ALCOHOLIC HEPATITIS WITH CC | $29,185 | $18,970 | — | — | 58 |
| 561 | AFTERCARE, MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITHOUT CC/MCC | $27,791 | $18,064 | — | — | 57 |
| 190 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH MCC | $27,006 | $17,554 | — | — | 58 |
| 919 | COMPLICATIONS OF TREATMENT WITH MCC | $26,427 | $17,178 | — | — | 54 |
| 603 | CELLULITIS WITHOUT MCC | $23,273 | $15,128 | — | — | 57 |
| 950 | AFTERCARE WITHOUT CC/MCC | $23,080 | $15,002 | — | — | 58 |
| 381 | COMPLICATED PEPTIC ULCER WITH CC | $21,745 | $14,134 | — | — | 57 |
| RX-80908 | DIGOXIN IMMUNE FAB 40 MG INTRAVENOUS SOLUTION | $21,524 | $13,990 | — | — | 103 |
| 388 | GASTROINTESTINAL OBSTRUCTION WITH MCC | $17,792 | $11,565 | — | — | 57 |
| RX-129357 | DARBEPOETIN ALFA 500 MCG/ML IN POLYSORBATE INJECTION SYRINGE | $17,415 | $11,320 | — | — | 108 |
| 637 | DIABETES WITH MCC | $16,867 | $10,963 | — | — | 58 |
| 192 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITHOUT CC/MCC | $15,815 | $10,280 | — | — | 58 |
| 202 | BRONCHITIS AND ASTHMA WITH CC/MCC | $15,225 | $9,896 | — | — | 58 |
| 439 | DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITH CC | $14,755 | $9,591 | — | — | 58 |
| RX-245937 | HUMAN PROTHROMBIN CMPX(PCC)-LANS 1,000 UNIT (800-1,280 UNIT) IV SOLUTION | $14,175 | $9,214 | — | — | 107 |
| 392 | ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MCC | $13,935 | $9,058 | — | — | 58 |
| 057 | DEGENERATIVE NERVOUS SYSTEM DISORDERS WITHOUT MCC | $11,785 | $7,660 | — | — | 58 |
| 638 | DIABETES WITH CC | $11,340 | $7,371 | — | — | 58 |
| 440 | DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITHOUT CC/MCC | $9,897 | $6,433 | — | — | 58 |
| 191 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CC | $9,856 | $6,407 | — | — | 58 |
| RX-232982 | EPTINEZUMAB-JJMR 100 MG/ML INTRAVENOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $9,441 | $6,136 | — | — | 108 |
| RX-190284 | DENOSUMAB 60 MG/ML SUBCUTANEOUS SYRINGE|RX AMT DISCARD/NOT ADMIN TO PT | $9,377 | $6,095 | — | — | 108 |
| RX-253466 | DENOSUMAB-BMWO 60 MG/ML SUBCUTANEOUS SYRINGE|RX AMT DISCARD/NOT ADMIN TO PT | $8,908 | $5,790 | — | — | 104 |
| RX-209792 | DALBAVANCIN 500 MG INTRAVENOUS SOLUTION | $8,006 | $5,204 | — | — | 108 |
| RX-245938 | HUMAN PROTHROMBIN CPLX(PCC)-LANS 500 UNIT (400-640 UNIT) IV SOLUTION | $7,088 | $4,607 | — | — | 107 |
| RX-129718 | DARBEPOETIN ALFA 200 MCG/0.4 ML IN POLYSORBATE INJECTION SYRINGE | $6,966 | $4,528 | — | — | 108 |
| RX-196284 | HYDROXOCOBALAMIN 5 GRAM INTRAVENOUS SOLUTION | $6,717 | $4,366 | — | — | 103 |
| 305 | HYPERTENSION WITHOUT MCC | $6,485 | $4,215 | — | — | 58 |
| PX-100001753 | App Skn Sub Trk/Arm/Leg 1st 100sqcm Twsa >=100 Sqcm | $6,189 | $4,023 | — | — | 104 |
| RX-300910 | ALTEPLASE 1 MG/ML IV SOLUTION | $5,940 | $3,861 | — | — | 108 |
| PX-700000668 | Cta Abd Aorta Bi Iliofem W/WO | $5,444 | $3,539 | — | — | 108 |
| PX-100001757 | App Skn Sub Hd/Nk/Hnd/Ft 1st 100sqcm< Twsa>=100 Sqcm | $5,311 | $3,452 | — | — | 104 |
| PX-500002004 | Arthroplasty Hip Total Pf | $5,255 | $3,416 | — | — | 107 |
| CASE-99285 | ED Visit Care Level 5 | $5,087 | $3,307 | — | — | 7 |
| RX-182466 | FERUMOXYTOL 510 MG/17 ML (30 MG/ML) INTRAVENOUS SOLUTION | $4,972 | $3,232 | — | — | 108 |
| PX-500001992 | Arthroplasty Total Shoulder Pf | $4,938 | $3,210 | — | — | 107 |
Showing top 50 of 1,869 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.